Nudix hydrolase 15

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Nudix Hydrolase 15 or NUDT15 or NUDT15D refers to either a gene or the enzyme encoded by it.[1]

Function[edit | edit source]

NUDT15 expression affects the way that certain immunosuppressant drugs work.

Drug responses and genetic testing[edit | edit source]

Genetic testing for NUDT15 aims to improve clinical outcomes and reduce harm in people with inherited genetic mutations known to agfect drug responses.[2]

There are a wide variety of different varoations, which may be broadly grouped into:

  • Normal Metabolizer: Two copies of a normal function allele in the NUDT15 gene.
  • Intermediate Metabolizer: One copy of a normal function allele and one copy of a no function allele in the NUDT15 gene.
  • Poor Metabolizer: Two copies of no function alleles, low or absent activity of NUDT15. At high risk for toxicity with normal doses of thiopurine drugs.
  • Possible Intermediate Metabolizer: One copy of a normal function allele and one copy of an uncertain function allele in the NUDT15 gene. At risk for myelosuppression with thiopurine drugs.
  • Possible Poor Metabolizer: Two copies of uncertain function alleles or one copy of an uncertain function allele and one no function allele in the NUDT15 gene. At high risk for toxicity with thiopurine drugs.
  • Indeterminate-Phasing Positive: Uncharacterized allele composition.[3]

ME/CFS[edit | edit source]

Genetic studies of ME/CFS patients have not so far identified any TPMT genes as possibly associated with ME/CFS.[4]

Thiopurine drugs have not been suggested as potentially useful for ME/CFS, and there is no guidance to avoid them.[5][6][7]

Notable studies[edit | edit source]

  • 2019, Dietary intakes and biomarker patterns of folate, vitamin B6, and vitamin B12 can be associated with cognitive impairment by hypermethylation of redox-related genes NUDT15 and TXNRD1[8] - (Full text)

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "NUDT15 Gene - Nudix Hydrolase 15". Gene cards. Retrieved April 7, 2022.
  2. Royal College of Physicians; British Pharmacological Society (2022), Personalised prescribing: using pharmacogenomics to improve patient outcomes. Report of a working party., London: RCP and BPS
  3. "Nudix Hydrolase 15 (NUDT15) Genotyping" (PDF). RDRX Diagnostics. Retrieved April 8, 2022.
  4. Dibble, Joshua J; McGrath, Simon J; Ponting, Chris P (August 3, 2020). "Genetic risk factors of ME/CFS: a critical review". Human Molecular Genetics. 29 (R1): R117–R124. doi:10.1093/hmg/ddaa169. ISSN 0964-6906. PMC 7530519. PMID 32744306.
  5. Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, AC Peter; Sherkey, Jeffrey A.; van de Sande, Marjorie I. (2003), "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols" (PDF), Journal of Chronic Fatigue Syndrome, 11 (2): 7–115, doi:10.1300/J092v11n01_02
  6. Carruthers, BM; van de Sande, MI; De Meirleir, KL; Klimas, NG; Broderick, G; Mitchell, T; Staines, D; Powles, ACP; Speight, N; Vallings, R; Bateman, L; Bell, DS; Carlo-Stella, N; Chia, J; Darragh, A; Gerken, A; Jo, D; Lewis, DP; Light, AR; Light, KC; Marshall-Gradisnik, S; McLaren-Howard, J; Mena, I; Miwa, K; Murovska, M; Stevens, SR (2012), Myalgic encephalomyelitis: Adult & Paediatric: International Consensus Primer for Medical Practitioners (PDF), ISBN 978-0-9739335-3-6
  7. NICE Guideline Development Group (October 29, 2021). "Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome:diagnosis and management. NICE guideline". National Institute for Health and Care Excellence.